Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
21 Gennaio 2025 - 2:00PM
Business Wire
Launch of Apollo™ for CRADL® provides a secure
cloud-based platform to enhance access to services and visibility
across teams and processes
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced the launch of Apollo™ for CRADL®, a secure cloud-based
platform that enhances leading vivarium rental services through a
digital platform that connects clients effortlessly with the
training, tools and services needed to start research quickly. As a
digital companion to CRADL’s existing rental space offering,
Apollo's centralized dashboard seamlessly connects clients to
online training, Charles River’s Research Models Online Ordering
System, and other study support services.
“Apollo is the tech stack that is powering Charles River’s
digital transformation,” said Mark Mintz, Corporate Senior Vice
President, Chief Information Officer at Charles River. “A high
impact, iteratively expanded platform that gives clients greater
access to data, products and services, across our portfolio, Apollo
enables data-driven decision making and accelerated operational
processes that creates value for our client’s businesses and drives
efficiencies in drug discovery and development.”
For CRADL clients, who are looking for simplified capability to
launch or expand drug discovery and development programs, Apollo
for CRADL streamlines onboarding, making the process of starting
research faster and easier within CRADL. Additionally, it provides
clients with direct control of reservations for technical services,
rooms, and equipment while facilitating protocol management and
IACUC committee communication to expedite research execution.
Apollo for CRADL is the latest in a series of innovations,
integrating the Apollo technology stack across Charles River’s
robust portfolio:
- Apollo for CRADL: Streamlines much of the required
administrative tasks associated with CRADL’s flexible vivarium
rental solutions, allowing clients to focus on starting their
programs faster, and enabling them to spend more time on their
research.
- Apollo for Safety Assessment: Expedites safety
assessment empowering clients with real-time access to data
visualization, milestones, documents, and program planning
tools.
- Apollo for Biologics: Provides a centralized platform to
submit sample submission forms, track samples, and exchange
documents all in one place, ensuring accuracy and saving time.
- Apollo for Discovery: Delivers instant access to
oncology study price estimates, unlocking a new world of speed and
accessibility, while providing access to oncology experts for study
purchasing, enhanced planning and budget approvals.
- Apollo for Logica®: Allows flexibility and agility for
clients in measuring success by delivering secure, near real-time
updates for Logica® AI powered small molecule programs.
- Research Models Online Ordering System: Delivers an
interactive catalog seamlessly connected to pricing systems and
real-time inventory to view availability linked to delivery
schedules, providing clients with a personalized purchasing
experience and immediate order confirmation.
Charles River is continuously expanding the scope of Apollo to
enhance client experience and drive increased efficiencies for
client studies at every stage of discovery and development.
About CRADL® CRADL®, the Charles River Accelerator and
Development Lab, is the leading space for clients to launch or
expand their in vivo drug research programs, with the added benefit
of access to Charles River’s complete portfolio of integrated drug
discovery and non-clinical development resources. The CRADL
vivarium network operates nearly 30 facilities, in key biohubs,
including Boston, San Francisco Bay, San Diego, Seattle,
Philadelphia, Chicago, Thousand Oaks, Shanghai, Chengdu, Suzhou,
and London. This network supports the growth of the entire biotech
ecosystem in each city, allowing researchers to rapidly progress
their science while maintaining the flexibility to expand, relocate
or co-locate, knowing they will have reliable, high-quality in vivo
facilities nearby.
About Charles River Charles River provides essential
products and services to help pharmaceutical and biotechnology
companies, government agencies and leading academic institutions
around the globe accelerate their research and drug development
efforts. Our dedicated employees are focused on providing clients
with exactly what they need to improve and expedite the discovery,
early-stage development and safe manufacture of new therapies for
the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250121865847/en/
Investor Contact: Todd Spencer, Corporate Vice President,
Investor Relations 781.222.6455 todd.spencer@crl.com
Media Contact: Amy Cianciaruso Corporate Vice President
& Chief Communications Officer +1-781-222-6168
amy.cianciaruso@crl.com
Grafico Azioni Charles River Laboratories (NYSE:CRL)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Charles River Laboratories (NYSE:CRL)
Storico
Da Gen 2024 a Gen 2025